Roula Ghaoui, FRACP; Sandra T. Cooper, PhD; Monkol Lek, PhD; et al.
free access
JAMA Neurol. 2015;72(12):1424-1432. doi:10.1001/jamaneurol.2015.2274
This study translates whole-exome sequencing to clinical practice for the genetic diagnosis of a large cohort of patients with limb-girdle muscular dystrophy for whom protein-based analyses and targeted Sanger sequencing failed to identify the genetic cause of their disorder.
Clinical Trial
Jeffrey Cohen, MD; Anna Belova, MD; Krzysztof Selmaj, MD; et al.
free access
JAMA Neurol. 2015;72(12):1433-1441. doi:10.1001/jamaneurol.2015.2154
This randomized clinical trial evaluates whether generic glatiramer acetate is equivalent to the regulatory-approved brand glatiramer acetate product, as measured by imaging and clinical end points, safety, and tolerability, for treatment of relapsing-remitting multiple sclerosis.
Davinia Fernández-Espejo, PhD; Stephanie Rossit, PhD; Adrian M. Owen, PhD
free access
JAMA Neurol. 2015;72(12):1442-1450. doi:10.1001/jamaneurol.2015.2614
This case-control study examined the neural substrates and underlying networks associated with dissociation between preserved covert motor behavior and lack of overt motor behavior in behaviorally nonresponsive patients.
Shadi Yaghi, MD; Amelia K. Boehme, MSPH, PhD; Jamil Dibu, MD; et al.
free access
JAMA Neurol. 2015;72(12):1451-1457. doi:10.1001/jamaneurol.2015.2371
This multicenter study investigates the natural history of thrombolysis-related symptomatic intracerebral hemorrhage and in-hospital mortality, with a focus on the efficacy of various treatments used.
Kathryn C. Fitzgerald, ScM; Kassandra L. Munger, ScD; Karl Köchert, MD; et al.
free access
JAMA Neurol. 2015;72(12):1458-1465. doi:10.1001/jamaneurol.2015.2742
This observational study of patients with multiple sclerosis examines the association between 25-dihydroxyvitamin D levels and the signs of progression of multiple sclerosis.
Serena Ruggieri, MD; Maria Petracca, MD; Aaron Miller, MD; et al.
free access
JAMA Neurol. 2015;72(12):1466-1474. doi:10.1001/jamaneurol.2015.1897
This cross-sectional study of patients with primary progressive multiple sclerosis assesses the correlation between the neurodegenerative process in the gray and white matter structures and the spinal cord and its effect on clinical disabililty.
David S. Knopman, MD; Clifford R. Jack Jr, MD; Emily S. Lundt, MS; et al.
free access
JAMA Neurol. 2015;72(12):1475-1483. doi:10.1001/jamaneurol.2015.2323
This longitudinal, observational study with serial brain imaging aimed to define the role of β-amyloidosis and neurodegeneration in the subsequent progression of topographic cortical structural and metabolic changes in mild cognitive impairment.
Jonathan Gooblar, MA; Catherine M. Roe, PhD; Natalie J. Selsor, MSW; et al.
free access
JAMA Neurol. 2015;72(12):1484-1490. doi:10.1001/jamaneurol.2015.2875
This survey reports on the attitudes of cognitively normal longitudinal aging study participants and members of the general public regarding disclosure of Alzheimer disease research results.
Clinical Trial
Robert A. Hauser, MD; Fabrizio Stocchi, MD; Olivier Rascol, MD; et al.
free access
JAMA Neurol. 2015;72(12):1491-1500. doi:10.1001/jamaneurol.2015.2268
Two randomized clinical trials evaluated preladenant as an adjunct to levodopa in patients with moderate to severe Parkinson disease who were experiencing motor fluctuations.
Emma Devenney, MRCP; Lauren Bartley, BSc; Chris Hoon, BSc; et al.
free access
JAMA Neurol. 2015;72(12):1501-1509. doi:10.1001/jamaneurol.2015.2061
This cohort study of patients with possible and probable behavioral variant frontotemporal dementia identified features of progression that may help clinicians determine the rates of progression to definite disease.